JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA

Key Points

• JPMorgan Chase & Co. reduced its stake in Tyra Biosciences by 27.9% in Q3, selling 28,688 shares and retaining 74,229 shares worth about $1.04 million (≈0.14% of the company).
• Director Gilla Kaplan sold 14,295 shares at an average price of $36.97—cutting her holding by 33.61%—while insiders own 15.20% of the stock and institutional investors own 84.14%.
• TYRA trades around $35.29 with a market cap of $1.90 billion and a 12‑month range of $7.52–$40.65; analysts give a consensus rating of “Moderate Buy” with a $45.43 average price target.

JPMorgan Chase & Co. lessened its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 27.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 74,229 shares of the company's stock after selling 28,688 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.14% of Tyra Biosciences worth $1,038,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Federated Hermes Inc. raised its position in shares of Tyra Biosciences by 586.3% in the 3rd quarter. Federated Hermes Inc. now owns 2,155 shares of the company's stock worth $30,000 after buying an additional 1,841 shares during the period. SG Americas Securities LLC purchased a new position in shares of Tyra Biosciences in the 3rd quarter worth $133,000. Russell Investments Group Ltd. raised its position in shares of Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company's stock worth $178,000 after buying an additional 2,766 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company's stock worth $126,000 after buying an additional 1,668 shares during the period. Finally, Public Employees Retirement System of Ohio raised its position in shares of Tyra Biosciences by 34.8% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 24,962 shares of the company's stock worth $349,000 after buying an additional 6,450 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Price Performance

NASDAQ:TYRA opened at $35.29 on Friday. The business's 50-day moving average is $34.32 and its two-hundred day moving average is $25.44. Tyra Biosciences, Inc. has a 12 month low of $7.52 and a 12 month high of $40.65. The firm has a market capitalization of $1.90 billion, a PE ratio of -17.56 and a beta of 0.96.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). Equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Analyst Upgrades and Downgrades

TYRA has been the topic of several research reports. Canaccord Genuity Group initiated coverage on Tyra Biosciences in a research report on Monday, April 6th. They issued a "buy" rating and a $50.00 target price on the stock. Cantor Fitzgerald initiated coverage on Tyra Biosciences in a research report on Tuesday, February 24th. They issued an "overweight" rating on the stock. William Blair initiated coverage on Tyra Biosciences in a research report on Tuesday, February 10th. They issued an "outperform" rating on the stock. Jefferies Financial Group increased their target price on Tyra Biosciences from $32.00 to $43.00 and gave the stock a "buy" rating in a research report on Tuesday, February 3rd. Finally, Wedbush raised their price objective on Tyra Biosciences from $37.00 to $53.00 and gave the company an "outperform" rating in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tyra Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $45.43.

Insider Buying and Selling

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the firm's stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company's stock, valued at $1,043,700.07. This trade represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.20% of the stock is owned by company insiders.

Tyra Biosciences Profile

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.